Core Thesis - Edwards Lifesciences Corporation (EW) is viewed positively as a stock investment, with a current trading price of $83.92 and trailing and forward P/E ratios of 46.17 and 28.49 respectively [1]. Company Overview - Edwards Lifesciences specializes in products and technologies for advanced cardiovascular diseases, having transitioned into a pure-play leader in structural heart disease after divesting its Critical Care business for $4.2 billion [2]. Financial Performance - The divestiture removed approximately 20% of the company's 2023 EBITDA base, but this has been offset by the rapid growth of the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, which is expanding over 50% year-over-year [3]. - The core Transcatheter Aortic Valve Replacement (TAVR) franchise generates over $4.5 billion in annual revenue with growth exceeding 12%, providing a stable foundation for the company [4]. Valuation and Investment Potential - Following a recent pullback, Edwards Lifesciences is trading at approximately $78, supported by strong fundamentals such as 78% gross margins and a solid balance sheet with $3.8 billion in cash [5]. - The company's valuation of around 21.3x EV/NTM EBITDA is below its historical average of 26x, indicating potential for multiple expansion alongside expected EBITDA growth of 10-11% CAGR [5]. Growth Outlook - With ongoing share repurchases and disciplined capital allocation, Edwards Lifesciences is positioned for sustained double-digit earnings growth, driven by demographic trends and innovation in transcatheter therapies [6]. - A favorable scenario combining earnings expansion and multiple re-rating could lead to compelling double-digit annualized returns from current levels [6].

Group 1 - Edwards Lifesciences Corp. has shown stable share performance following a solid year in 2025, focusing on heart-related products [2] - The investment group community offers access to real-time portfolios and in-depth research on corporate events such as IPOs and mergers [1] - The Value Investor, with a Master of Science in financial markets, leads the investment group and provides opportunities to capitalize on significant corporate events [2] Group 2 - The investment group covers approximately 10 major corporate events each month, aiming to identify the best investment opportunities [2]

Core Insights - Edwards Lifesciences (EW) has achieved a remarkable 22.1% return over the past year, significantly outperforming the industry's decline of 3.8% and closely aligning with the S&P 500's rise of 23.5% [1][8] Company Performance - The company is currently ranked 2 (Buy) by Zacks and has shown consistent growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, while effectively scaling its fast-growing businesses [2] - The Transcatheter Aortic Valve Replacement (TAVR) platform has benefited from technological advancements like RESILIA and increased global adoption, with TAVR sales exceeding $1 billion for the fifth consecutive quarter [2][6] - The Surgical Structural Heart business is experiencing robust uptake of premium surgical technologies globally, contributing to overall growth [2][10] Recent Developments - On September 3, 2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson, and Company for $4.2 billion, enhancing its balance sheet flexibility for investments in new technologies [3] - The company has seen strong momentum in the TMTT segment, driven by the global adoption of PASCAL and EVOQUE systems, which provide solutions for mitral and tricuspid patients [4][8] - The EVOQUE system became eligible for all Medicare beneficiaries with symptomatic tricuspid regurgitation in March 2025, and the SAPIEN M3 mitral valve replacement system received CE Mark approval in April 2025 [5] Financial Estimates - The Zacks Consensus Estimate projects a 14.8% increase in earnings per share (EPS) for 2026 to $2.94 and a 12.2% increase for 2027 to $3.30, with revenues expected to grow 9.6% to $6.65 billion in 2026 and 9.8% to $7.30 billion in 2027 [12]

Core Insights - Edwards Lifesciences Corp is a key player in the healthcare sector, focusing on heart valve technologies and critical care monitoring [1] Group 1: Company Actions and Leadership - Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, sold 1,019 shares at approximately $85.38 each but retains around 33,934 shares, indicating confidence in the company's future [1][5] - The company's participation in the Leerink Global Healthcare Conference 2026 highlights its commitment to innovation and strategic growth [2][5] Group 2: Financial Metrics - Edwards Lifesciences has a high price-to-earnings (P/E) ratio of 46.15, reflecting a positive market outlook on its growth potential [2] - The price-to-sales ratio stands at 8.14, indicating that investors are willing to pay over eight times the company's sales per share, showcasing confidence in its revenue-generating capabilities [3] - The enterprise value to sales ratio is 7.78, suggesting a strong valuation when accounting for debt and cash [3] - The company maintains a low debt-to-equity ratio of 0.068, indicating a conservative approach to leveraging debt [4] - A strong current ratio of 3.72 demonstrates that Edwards Lifesciences has sufficient current assets to cover its liabilities, ensuring liquidity and operational stability [4]

Core Insights - The business has significantly evolved over the past year, particularly in the TAVR segment, with a pivotal event being the presentation of early clinical trial data in late 2024, which addressed durability concerns of the SAPIEN valve family [1] - The early TAVR data, especially regarding asymptomatic patients, has generated considerable momentum for the business in 2025 [1] Group 1 - The 7-year trial data on the durability of SAPIEN valves has been influential, particularly in the PARTNER 3 low-risk study [2]

Summary of Edwards Lifesciences Conference Call Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Technology, specifically focusing on heart valve therapies and surgical solutions Key Points and Arguments TAVR (Transcatheter Aortic Valve Replacement) - **Clinical Data Impact**: The presentation of EARLY TAVR clinical trial data in late 2024 significantly boosted confidence in the durability of the SAPIEN valve family, leading to increased business momentum in 2025 [3][4] - **Growth Drivers**: The second half of 2025 saw a 10.6% growth in U.S. TAVR, attributed to increased urgency in treating severe aortic stenosis, driven by new clinical data [9][10] - **2026 Growth Guidance**: Projected TAVR growth of 6%-8% for 2026, with confidence in this guidance due to a global footprint of approximately 2,000 sites performing SAPIEN procedures [11][12] - **NCD and Guidelines**: Upcoming National Coverage Determination (NCD) and updates to U.S. guidelines are critical for future TAVR performance [14][15] TMTT (Transcatheter Mitral and Tricuspid Therapies) - **Portfolio Expansion**: For the first time, Edwards offers both repair and replacement solutions for mitral and tricuspid regurgitation, enhancing its position as a partner for physicians [5][24] - **Market Dynamics**: The TMTT market is growing, with PASCAL being the current revenue leader, while EVOQUE is growing at a faster rate [26][27] - **Clinical Trials**: Upcoming clinical trial data, such as CLASP II TR and TRISCEND II, are expected to provide insights into the performance of PASCAL and EVOQUE [29][30] Surgical Innovations - **New Solutions**: Edwards is preparing to introduce a left atrial appendage (LAA) closure solution, complementing its existing surgical portfolio [47][48] - **Investment in Surgical**: Continued investment in surgical innovations reflects the company's commitment to expanding its offerings in valvular disease treatment [48] Financial Performance - **Gross Margin Guidance**: Expected gross profit margin of 78%-79% for 2026, with operating profit margin projected to grow by 150 basis points [51] - **R&D Investments**: R&D as a percentage of sales is expected to decrease from 19.4% in 2024 to around 17% in 2026, indicating a focus on efficiency while driving innovation [53][54] Capital Allocation and M&A Strategy - **External Investments**: Edwards is open to external investments, focusing on early-stage technologies that complement internal innovations in structural heart [55][56] Innovation Focus - **Core Strategy**: The company emphasizes the importance of innovation as the foundation of its culture and business strategy, aiming to maintain leadership in the structural heart market [57] Additional Important Insights - **Physician Engagement**: The company is focused on improving treatment rates for patients with mitral and tricuspid regurgitation, rather than merely capturing market share [26] - **Patient Outcomes**: Positive anecdotal evidence from patients treated with EVOQUE highlights the significant impact of the therapy on quality of life [32] This summary encapsulates the key discussions and insights from the Edwards Lifesciences conference call, providing a comprehensive overview of the company's current position and future outlook in the medical technology industry.

Core Insights - The discussion centers around the sustainable growth potential of Edwards, particularly focusing on achieving double-digit growth consistently [1] Group 1: Business Performance - There is an emphasis on the established TAVR (Transcatheter Aortic Valve Replacement) business and its growth opportunities [1] - The conversation highlights the importance of understanding the components that contribute to sustainable growth within the company [1] Group 2: Emerging Opportunities - The faster-growing emerging businesses under TMTT (Transcatheter Mitral and Tricuspid Therapies) are noted as significant contributors to future growth [1] - The need to piece together insights from both established and emerging segments is crucial for evaluating overall growth potential [1]

Edwards Lifesciences FY Conference Summary Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Date of Conference**: March 10, 2026 - **Key Speakers**: Scott Ullem (CFO), Mark Wilterding (Head of Investor Relations), Sydney Bailey (Investor Relations Team) Core Industry Insights - **Sustainable Growth**: Edwards Lifesciences aims for double-digit sustainable growth, driven by established TAVR business and emerging TMTT (Transcatheter Mitral and Tricuspid Therapies) [3][4] - **TAVR Business**: TAVR remains a cornerstone of growth, expected to grow mid-single digits annually [7] - **TMTT Growth**: TMTT is projected to reach $2 billion in revenue by 2030, with expected growth rates of 35%-45% in 2026 [7][8] Financial Projections - **TMTT Revenue**: Expected to grow from over $500 million in 2025 to $740 million-$780 million in 2026 [8] - **Overall Growth Expectation**: Anticipated double-digit growth of approximately 10% annually, combining TAVR, TMTT, and surgical business performance [8] Product Development and Market Strategy - **Innovative Therapies**: Introduction of new therapies like PASCAL for mitral and tricuspid, and SAPIEN M3 for mitral valve replacement, providing options for patients historically limited to surgical interventions [10][11] - **Heart Failure Management**: Development of Cordella device for heart failure management, addressing a significant patient population with limited treatment options [16][17] - **Aortic Regurgitation**: Acquisition of technology for catheter-based replacement of diseased aortic valves, with a focus on addressing different disease states [21][22] Market Opportunities - **EARLY TAVR Trial**: Results from the trial indicate the need for valve replacement in severe aortic stenosis patients regardless of symptoms, leading to increased physician interest [25][26] - **CMS Evaluation**: Anticipation of a more accommodating National Coverage Determination (NCD) to facilitate patient referrals for valve replacement [26] Long-term Vision - **Comprehensive Care**: Emphasis on developing multi-device and multi-therapy solutions for patients at risk of heart failure, recognizing the interplay between different structural heart conditions [20][21] - **Strategic Investments**: Commitment to investing in technologies that align with core competencies, particularly in structural heart failure [21] Additional Considerations - **Patient Eligibility**: Importance of a toolkit approach to cater to diverse patient anatomies and treatment needs, ensuring tailored therapeutic interventions [13] - **Market Dynamics**: Recognition of differing opinions within the medical community regarding the timing of treatment for aortic stenosis patients [28]

Summary of Edwards Lifesciences FY Conference Call (March 10, 2026) Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Devices, specifically focusing on heart valve therapies and structural heart disease solutions Key Points and Arguments Growth Strategy - **Sustainable Growth**: The company aims for double-digit sustainable growth through investments in differentiated technologies and platforms that address large patient populations [5][6] - **TAVR Business**: Transcatheter Aortic Valve Replacement (TAVR) remains a cornerstone of growth, driving innovation and revenue [5][6] - **Emerging Businesses**: The Transcatheter Mitral and Tricuspid Therapies (TMTT) are expected to grow significantly, with a long-term revenue target of $2 billion by 2030 [8][9] Financial Projections - **TMTT Growth**: Expected to grow from over $500 million in 2025 to $740 million-$780 million in 2026, with a growth rate of 35%-45% [9] - **TAVR Growth**: Projected to grow mid-single digits annually, indicating a shift as TMTT becomes a larger contributor to overall growth [8][9] Product Development - **Innovative Therapies**: Introduction of new therapies such as SAPIEN M3 for mitral valve replacement and EVOQUE for tricuspid replacement, providing options for patients historically limited to surgical interventions [11][12] - **Heart Failure Management**: Development of the Cordella device for heart failure management, indicating a strategic move into this area due to the lack of treatment options [17][18] Market Dynamics - **Early TAVR Trial**: Results from the Early TAVR trial have shifted physician perspectives on treating aortic stenosis, emphasizing the need for valve replacement regardless of symptoms [25][37] - **Regulatory Environment**: Anticipation of changes in national coverage determinations (NCD) to facilitate easier access for patients needing valve replacements [26] Operational Considerations - **Margin Expansion**: The company expects about 150 basis points of operating margin expansion this year, with a long-term goal of 50-100 basis points annually [40] - **Investment in Growth**: Emphasis on balancing investments in R&D and market development with achieving margin expansion [40][42] Risk Factors - **Market Competition**: The company faces competition in the TMTT space, particularly as it seeks to capture market share from established players [10][11] - **Geopolitical Concerns**: Current focus on employee safety in the Middle East amid regional tensions, with uncertain long-term impacts on operations [45] Additional Important Insights - **Comprehensive Care Approach**: The company is exploring multi-device and multi-therapy solutions for patients at risk of heart failure, indicating a long-term strategy to address complex patient needs [20][21] - **Technological Investments**: Ongoing investments in technologies like Vectorious for heart failure management, showcasing a commitment to expanding treatment options for underserved patient populations [18][22] This summary encapsulates the key discussions and insights from the Edwards Lifesciences FY Conference Call, highlighting the company's strategic direction, financial outlook, and operational challenges.

Industry Overview - The U.S. medical instrument industry has stabilized entering 2026 after years of volatility due to inflation, rising interest rates, and uneven hospital spending, with procedure volumes normalizing post-pandemic [1] - Providers are cautious on capital budgets, focusing on productivity, reliability, and total cost of ownership [1] - The Medical - Instruments industry is ranked in the top 35% of the Zacks Industry Rank, indicating expected outperformance over the next three to six months [2] Company Highlights Intuitive Surgical Inc. (ISRG) - ISRG is integrating AI and digital tools into its robotic ecosystem, enhancing surgical performance metrics and providing real-time decision support [4][5] - The company has an expected revenue growth rate of 14.9% and earnings growth rate of 12.7% for the current year, with a Zacks Consensus Estimate for earnings improving by 0.5% [6] - The short-term average price target indicates a potential increase of 26% from the last closing price of $493.56, with a maximum upside of 52% [8] Globus Medical Inc. (GMED) - GMED's acquisition of Nevro and the merger with NuVasive are expected to strengthen its position in the musculoskeletal space and expand its product portfolio [9][10] - The company anticipates revenue growth of 8% and earnings growth of 7.5% for the current year, with earnings estimates improving by 6.7% [10] - The short-term average price target suggests a 24.7% increase from the last closing price of $87.81, with a maximum upside of 40.1% [11] Edwards Lifesciences Corp. (EW) - EW's Surgical Structural Heart business is benefiting from strong adoption of premium surgical technologies, with a focus on developing a comprehensive structural heart disease portfolio [12][13] - The expected revenue growth rate is 9.6% and earnings growth rate is 14.8% for the current year, with earnings estimates improving by 2.1% [14] - The short-term average price target indicates a 14% increase from the last closing price of $84.26, with a maximum upside of 30.5% [14] Alcon Inc. (ALC) - ALC is leveraging its Surgical and Vision Care segments for growth, with innovative products driving category leadership [15][16] - The expected revenue growth rate is 7.1% and earnings growth rate is 12.1% for the current year, with earnings estimates improving by 2.1% [16] - The short-term average price target suggests a 13.9% increase from the last closing price of $81.85, with a maximum upside of 36.8% [17] IRADIMED Corp. (IRMD) - IRMD specializes in MRI-compatible products and serves hospitals and outpatient imaging centers [18][19] - The expected revenue growth rate is 10.8% and earnings growth rate is 8.8% for the current year, with earnings estimates remaining stable [20] - The short-term average price target indicates a 19.9% increase from the last closing price of $100.18, with a maximum upside of 20% [20]